Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD | #ASH24

Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD | #ASH24
Daratumumab vs Lenalidomide As Myeloma Maintenance Therapy | Sridevi Rajeeve, MD | #ASH24
What is MGUS?
MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24
Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24
Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24
Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24
Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24
Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24
Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24
The Unique Power of Whole Genome Sequencing in Multiple Myeloma | Francesco Maura, MD | #ASH24
Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD | #ASH24
Tri-specific Antibody SAR442257 in RRMM and Non-Hodgkin Lymphoma | Fredrik Schjesvold, MD, PhD | #ASH24